PDA is not specifically listed as a Category 2 substance
It works through three receptor pathways at once: GLP-1 reduces appetite and slows digestion, GIP supports insulin sensitivity, and glucagon raises energy expenditure and fat oxidation
Clinical trials, such as Falutz et al., New England Journal of Medicine (2010), found significant reductions in VAT among patients treated with Tesamorelin
Bridge medications are incretin-based therapies (Wegovy and Foundayo are GLP-1 receptor agonists
Nevertheless, it is important to recognize that these findings may not directly translate to clinical settings
However, IV administration of any substance (including glutathione) in volumes exceeding 100mL per 12-hour period is prohibited under WADA rules unless medically justifiedathletes using IV glutathione drips for recovery or cosmetic purposes must ensure the volume stays below the threshold or obtain a therapeutic use exemption